Eupraxia Pharmaceuticals Inc.
TSX:EPRX.TO · Toronto Stock Exchange
+$0.22 today
Vol 0.02M · Avg 0.05M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-47.9%
avg -221.6%
ROIC
-48.6%
avg -37.5%
ROA
-45.6%
avg -160.1%
Analysis
ROA is currently the strongest return metric at -45.6% versus its period average of -160.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
James A. Helliwell FRCPC | Chief Executive Officer & Director | $943,028.00 | — | 52 | — | — |
Mark Kowalski | Chief Medical Officer | $790,957.00 | — | 71 | — | — |
Jeymi Tambiah | Chief Medical Officer | $790,957.00 | — | — | — | — |
Alexander John Rothwell | Chief Financial Officer | $574,454.00 | — | 57 | — | — |
Paul Anthony Brennan | Chief Corporate Development Officer | $507,316.00 | — | — | — | — |
Amanda Malone | Chief Scientific Officer & Chief Operating Officer | $462,470.00 | — | 45 | — | — |
Alex Therien | Executive VP of R&D | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
NervGen Pharma Corp.
NGEN.V
$407.94M
Fennec Pharmaceuticals Inc.
TSX:FRX.TO
$360.97M
Medical Facilities Corporation
TSX:DR.TO
$315.73M
Profound Medical Corp.
TSX:PRN.TO
$285.95M
TerrAscend Corp.
TSX:TSND.TO
$283.25M
Canopy Growth Corporation
TSX:WEED.TO
$245.35M
OrganiGram Holdings Inc.
TSX:OGI.TO
$188.33M
Cybin Inc.
CYBN.NE
$154.92M
Helix BioPharma Corp.
TSX:HBP.TO
$108.46M
Medicenna Therapeutics Corp.
MDNA.TO
$28.53M
Who manages EPRX.TO?
Eupraxia Pharmaceuticals Inc. (EPRX.TO) lists 7 active executives. The top listed executive is Alex Therien, Executive VP of R&D.
Explore More
Continue the stock analysis
Jump to another research area for this company.